In recent decades, the clinical application of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) has improved the survival of patients with non-small cell lung cancer(NSCLC), which also remarkably promote the standardization of EGFR and EML4-ALK testing in patients with advanced lung cancer and the development of individualized targeted therapy for advanced NSCLC.However, the co-existing mutation of EGFR and ALK gene is rare compared with single mutation of them, the clinical features and optimal targeted therapy of double-positive patients are not clear yet.Therefore, this paper aims to review the reports of NSCLC patients with double EGFR mutation and EML4-ALK rearrangement.

Carcinoma, non-small-cell lung; Receptor, epidermal growth factor; Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; Co-existing mutation